Literature DB >> 16403602

DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human.

Kenneth Blum1, Brian Meshkin, B William Downs.   

Abstract

We hypothesize that using a multi-variant nutrigenomic index for the purposes of customizing or adjusting the formulation of nutritional supplements will result in an improved and novel approach to the diagnosis, stratification, prognosis, and treatment of inflammatory processes in the human. This multi-variant genetic index, or Genoscore, is derived by analyzing genotype and/or phenotype through measuring multiple genetic mutations of single nucleotide polymorphisms, gene expression, or other forms of genetic and phenotypic measurements. We also propose that manipulation of neurochemical reward circuitry in the mesolimbic brain region providing dopamine release at the nucleus accumbens (NAc), will have both pain and stress relief benefists, which are a cornerstone to the human inflammatory process. This hypothesis, applies to all genes currently discovered or which will be discovered and any nutritional or dietary supplement ingredient currently available or which will become available. For example, if a DNA test was measuring two genes through single nucleotide polymorphisms (Gene A and Gene B), the index scores (Genoscore) that would be reported to the clinician and patient would be based upon the number of mutations. An index score of 0 would mean no mutation. An index score of 1 may mean a mutation in Gene A. An Index Score of 2 may mean a mutation in Gene B. An Index Score of 3 may mean a mutation in Gene A and Gene B, resulting in a simple report, easily understandable to both the clinician and patient that provides insights into disease diagnosis, stratification, prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients and other ingredients in the nutritional and/or dietary supplement regimen. Furthermore, we have provided support that evidence shows the importance of the dopaminergic connection as an anti-pain and anti-stress molecule, working at the mesocorticolimbic region of the brain, specifically at the NAc. Additionally, we have provided support that clinical evidence demonstrates the effectiveness and safety of natural substances for joint health, such as glucosamine sulfate , chondroitin sulfate, and Ganoderma lucidum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16403602     DOI: 10.1016/j.mehy.2005.09.029

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

1.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Margaret A Madigan; Lyle Fried; Eric R Braverman; John Giordano; Rajendra D Badgaiyan
Journal:  Glob J Addict Rehabil Med       Date:  2017-02-23

2.  Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?

Authors:  B William Downs; Amanda L C Chen; Thomas J H Chen; Roger L Waite; Eric R Braverman; Mallory Kerner; Dasha Braverman; Patrick Rhoades; Thomas J Prihoda; Tomas Palomo; Marlene Oscar-Berman; Jeffrey Reinking; Seth H Blum; Nicholas A DiNubile; H H Liu; Kenneth Blum
Journal:  Med Hypotheses       Date:  2009-05-17       Impact factor: 1.538

3.  Attention-deficit-hyperactivity disorder and reward deficiency syndrome.

Authors:  Kenneth Blum; Amanda Lih-Chuan Chen; Eric R Braverman; David E Comings; Thomas J H Chen; Vanessa Arcuri; Seth H Blum; Bernard W Downs; Roger L Waite; Alison Notaro; Joel Lubar; Lonna Williams; Thomas J Prihoda; Tomas Palomo; Marlene Oscar-Berman
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.